Gameto’s $44M Series C to Help Redefine Reproductive Care, as First Patients Recruited for Pivotal Stem Cell Phase 3 Trial
AUSTIN, Texas, Aug. 12, 2025 /PRNewswire/ — Gameto, a clinical-stage biotechnology company developing stem cell-derived therapies for reproductive health, today announced the completion of a $44 million Series C financing round led by Overwater Ventures, with participation from Insight Partners,…